STOCK TITAN

Scorpius Holdings (SCPX) posts pro forma results after major asset foreclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K/A

Rhea-AI Filing Summary

Scorpius Holdings, Inc. filed an amended report to update pro forma financials after a December 10, 2025 foreclosure on its key operating assets. The sale transferred substantially all non-cash CDMO and research assets, with $15.2 million in net proceeds used to partially repay secured debt that totaled $30.2 million immediately before closing. Pro forma at September 30, 2025, total assets fall to $0.9 million and total stockholders’ deficit widens to $24.4 million. For the nine months ended September 30, 2025, pro forma revenue is eliminated and the net loss attributable to Scorpius narrows to $1.5 million as ongoing operations exclude the foreclosed businesses.

Positive

  • None.

Negative

  • Foreclosure of core operating assets: Substantially all non-cash CDMO and research assets were foreclosed on December 10, 2025, transferring the company’s primary operating assets to the buyer and terminating all CDMO employees.
  • Highly leveraged post-transaction balance sheet: After applying $15.2 million of sale proceeds, aggregate remaining related-party secured debt is still $14.9 million against pro forma total assets of only $0.9 million and a total stockholders’ deficit of $24.4 million.

Insights

Foreclosure removed core assets, cut losses, but left high leverage.

Scorpius Holdings lost substantially all non-cash CDMO and R&D assets in a December 2025 foreclosure. Net proceeds of $15.2 million reduced secured obligations that stood at $30.2 million immediately before closing, but a sizable debt load remains.

After applying proceeds, aggregate remaining related-party secured debt is $14.9 million, while pro forma total assets are only $0.9 million. Pro forma nine-month revenue falls to zero and the net loss attributable to Scorpius shrinks to $1.5 million, reflecting the removal of heavy loss-making operations.

The balance sheet shows total liabilities of $25.3 million and a total stockholders’ deficit of $24.4 million as of September 30, 2025. This amended disclosure mainly clarifies ongoing financial position and performance after treating the foreclosed business as discontinued operations.

true This Form 8-K/A amends the Current Report on Form 8-K, dated December 10, 2025 and filed on January 29, 2026 (the "Form 8-K") with respect to the unaudited pro forma condensed consolidated balance sheet and unaudited pro forma condensed consolidated statements of operations and comprehensive loss as of and for the six months ended June 30, 2025 contained in Item 9.01(b). As those financial statements were the most recent financial statements filed as of January 29, 2026, the purpose of this amendment is to replace those financial statements in their entirety with the unaudited pro forma condensed consolidated balance sheet and unaudited pro forma condensed consolidated statements of operations and comprehensive loss as of and for the nine months ended September 30, 2025. No other changes have been made to the Form 8-K. 0001476963 0001476963 2025-12-10 2025-12-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): December 10, 2025

 

Scorpius Holdings, Inc.

(Exact name of registrant as specified in charter)

 

 

Delaware  001-35994 26-2844103
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

1305 East Houston Street  
San Antonio, TX 78205
(Address of principal executive offices) (zip code)

 

(726) 201-5050

(Registrant’s telephone number including area code)

 

(Former Name and Former Address)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨  

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 
 
 
 

Explanatory Note    

This Form 8-K/A amends the Current Report on Form 8-K, dated December 10, 2025 and filed on January 29, 2026 (the “Form 8-K”) with respect to the unaudited pro forma condensed consolidated balance sheet and unaudited pro forma condensed consolidated statements of operations and comprehensive loss as of and for the six months ended June 30, 2025 contained in Item 9.01(b). As those financial statements were the most recent financial statements filed as of January 29, 2026, the purpose of this amendment is to replace those financial statements in their entirety with the unaudited pro forma condensed consolidated balance sheet and unaudited pro forma condensed consolidated statements of operations and comprehensive loss as of and for the nine months ended September 30, 2025. No other changes have been made to the Form 8-K.

 

Item 2.01.Completion of Acquisition or Disposition of Assets.

 

On December 10, 2025, certain assets of Scorpius Holdings, Inc. or its subsidiaries (collectively, the “Company”) were foreclosed upon (the “Disposed Assets”) as a result of a foreclosure sale pursuant to Article 9 of the Uniform Commercial Code conducted by the collateral agent (the “Collateral Agent”) on behalf of the holders of the senior secured convertible notes, dated as of December 6, 2024, issued by the Company in the aggregate original principal amount of $13,388,889 and non-convertible secured promissory notes issued by the Company in the aggregate principal amount of $9,841,765 (collectively, the “Secured Notes”). The Disposed Assets comprised substantially all non-cash assets of the Company and related to the Company’s CDMO and research and development activities and subsidiaries, which were encumbered by the Secured Notes and related security agreements.

 

The sale of the Disposed Assets constituted a disposition of a significant amount of assets for the purposes of Item 2.01 of Form 8-K. Accordingly, the pro forma financial information required by Item 9.01 is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 2.04.Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

 

The information set forth under Item 2.01 above of this Current Report on Form 8-K is incorporated by reference in this Item 2.04.

 

Item 9.01.Financial Statements and Exhibits.

 

(b) Pro forma financial information.

 

The following unaudited pro forma consolidated financial information (the “Pro Forma Information”) has been prepared to illustrate the estimated effects of the disposition of the Disposed Assets as if the transaction had occurred on:

 

·January 1, 2025, for the unaudited pro forma condensed consolidated balance sheet and unaudited pro forma condensed consolidated statements of operations and comprehensive loss as of and for the nine months ended September 30, 2025;

 

·January 1, 2024, for the unaudited pro forma consolidated statements of operations and comprehensive loss for the year ended December 31, 2024; and

 

·January 1, 2023, for the unaudited pro forma consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number
  Exhibit Description
99.1   Unaudited Pro Forma Consolidated Financial Information
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 10, 2026

SCORPIUS HOLDINGS, INC.

   
     
  By: /s/ Jeffrey Wolf
  Name:  

Jeffrey Wolf

  Title:

Chairman, President and

Chief Executive Officer

 

 

 

 

 

Exhibit 99.1

 

 

 

UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION

 

Description of the Transaction

 

On December 10, 2025, Scorpius Holdings, Inc. (the “Company”) lost ownership of certain assets (the “Disposed Assets”) as a result of a foreclosure sale pursuant to Article 9 of the Uniform Commercial Code conducted by 3i, LP in its capacity as collateral agent for certain secured notes and related security agreements.

 

The Disposed Assets comprised substantially all non-cash assets related to the Company’s CDMO and research and development activities and subsidiaries, which were encumbered by the secured notes and related security agreements. The collateral agent used the $15.2 million net proceeds from the foreclosure sale to partially settle the Company’s secured debt with a balance of $30.2 million immediately prior to the December 10, 2025 closing.

 

Employment of all CDMO employees terminated on December 10, 2025, and a majority of those former CDMO employees joined Velocity Bioworks, Inc., a wholly owned subsidiary of Tivic Health Systems, Inc. and buyer of the Disposed Assets.

 

The transaction meets the requirements for discontinued operations presentation and disclosure.

 

Basis of Pro Forma Presentation

 

The following unaudited pro forma consolidated financial information has been prepared to illustrate the estimated effects of the disposition of the Disposed Assets as if the transaction had occurred on:

 

  • January 1, 2025 for the unaudited pro forma condensed consolidated balance sheet and unaudited pro forma condensed consolidated statements of operations and comprehensive loss as of and for the nine months ended September 30, 2025
  • January 1, 2024 for the unaudited pro forma consolidated statements of operations and comprehensive loss for the year ended December 31, 2024
  • January 1, 2023 for the unaudited pro forma consolidated statements of operations and comprehensive loss for the year ended December 31, 2023

The pro forma financial information is presented for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been achieved had the disposition occurred on the assumed dates above and reflects only adjustments that are directly attributable to the foreclosure sale, factually supportable, and, with respect to the statements of operations, expected to have a continuing impact, in accordance with Article 11 of Regulation S-X. These unaudited pro forma condensed consolidated financial statements and the notes thereto should be read together with the Company’s audited consolidated financial statements and the notes thereto as of and for the years ended December 31, 2024 and 2023, and Management’s Discussion and Analysis included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as the Company’s unaudited condensed consolidated financial statements and the notes thereto as of and for the nine months ended September 30, 2025, and Management’s Discussion and Analysis included in the Company’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2025.

 

 
 

 

SCORPIUS HOLDINGS, INC.

Unaudited Pro Forma Condensed Consolidated Balance Sheet

 

             
   September 30, 2025 
 
 
 
 
Previously
Reported
 
 
 
 
Pro Forma
Adjustments
 
 
 
 
Pro Forma
Adjusted
 
 
Current Assets               
Cash and cash equivalents  $581,608   $   $581,608 
Short-term investments   19,178        19,178 
Accounts receivable   179,887        179,887 
Prepaid expenses and other current assets   1,137,478    (1,050,504)(a)   86,974 
Inventory - raw materials   203,483    (203,483)(b)    
Total Current Assets   2,121,634    (1,253,987)   867,647 
                
Long Term Assets               
Property and equipment, net   8,403,597    (8,403,597)(c)    
Operating lease right-of-use asset   577,705    (577,705)(d)    
Finance lease right-of-use asset   9,571,213    (9,571,213)(e)    
Deposits   96,826    (96,826)(f)    
Total Assets  $20,770,975   $(19,903,328)  $867,647 
                
Liabilities and Stockholders' Deficit               
                
Current Liabilities               
Accounts payable  $5,087,024   $   $5,087,024 
Deferred revenue   1,618,931        1,618,931 
Operating lease liability, current portion   184,943    (184,943)(d)    
Finance lease liability, current portion   1,151,975    (1,151,975)(e)    
Accrued expenses and other liabilities   2,881,210        2,881,210 
Convertible promissory notes payable, related party   8,862,000    6,318,205 (g)   15,180,205 
Non-convertible promissory notes payable, related party   2,410,000    (1,924,112)(g)   485,888 
Total Current Liabilities   22,196,083    3,057,175    25,253,258 
                
Long Term Liabilities               
Operating lease liability, net of current portion   555,936    (555,936)(d)    
Finance lease liability, net of current portion   4,951,684    (4,951,684)(e)    
Warrants   46,000        46,000 
Total Liabilities   27,749,703    (2,450,445)   25,299,258 
                
Stockholders' Deficit               
Common stock, $0.0002 par value; 250,000,000 shares authorized, 61,142,712 shares issued and outstanding at September 30, 2025   12,229        12,229 
Additional paid-in capital   301,508,976        301,508,976 
Accumulated deficit   (302,957,937)   (18,479,771)(h)   (321,437,708)
Accumulated other comprehensive income   107,036        107,036 
Total Scorpius Holdings, Inc. Stockholders' Deficit   (1,329,696)   (18,479,771)   (19,809,467)
Non-Controlling Interest   (5,649,032)   1,026,888    (4,622,144)
Total Stockholders' Deficit   (6,978,728)   (17,452,883)   (24,431,611)
                
Total Liabilities and Stockholders' Deficit  $20,770,975   $(19,903,328)  $867,647 
                

 

 

 

 
 

SCORPIUS HOLDINGS, INC.

Unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive Loss

 

             
   Nine Months Ended September 30, 2025 
   Previously
Reported
   Pro Forma
Adjustments
(j)  Pro Forma
Adjusted
 
             
Revenue  $669,640   $(669,640)  $ 
                
Operating expenses:               
Cost of revenues   735,185    (735,185)    
Research and development   8,423,716    (8,250,208)   173,508 
Selling, general and administrative   9,347,101    (4,494,156)   4,852,945 
Loss on lease assignment and termination   5,733,298    (4,132,767)   1,600,531 
Loss on disposal of long-lived assets   721,564        721,564 
Total operating expenses   24,960,864    (17,612,316)   7,348,548 
                
Operating loss   (24,291,224)   16,942,676    (7,348,548)
                
Interest income   1,565        1,565 
Interest expense   (575,163)   561,389    (13,774)
Loss on settlement of related party receivable   (780,000)       (780,000)
Loss on extinguishment of warrant liability   (279,000)       (279,000)
Loss on debt extinguishment   (2,647,000)   661,750 (j)   (1,985,250)
Change in fair value of warrant liability   2,331,000        2,331,000 
Change in fair value of related party receivable   230,000        230,000 
Change in fair value of non-convertible promissory notes, related party   1,300,000    (1,200,000)(k)   100,000 
Change in fair value of convertible promissory notes, related party   7,791,321    (1,630,330)(l)   6,160,991 
Other income, net   112,344    1,643    113,987 
Total non-operating income   7,485,067    (1,605,548)   5,879,519 
                
Net loss before income taxes   (16,806,157)   15,337,128    (1,469,029)
Income tax benefit            
Net loss   (16,806,157)   15,337,128    (1,469,029)
Net loss - non-controlling interest   (1,026,890)   1,026,890     
Net loss attributable to Scorpius Holdings, Inc.  $(15,779,267)  $14,310,238   $(1,469,029)
                
Weighted-average common shares outstanding, basic and diluted   38,667,703        38,667,703 
                
Net loss per common share attributable to Scorpius Holdings, Inc., basic and diluted  $(0.41)  $0.37   $(0.04)
                
Comprehensive loss               
Net loss  $(16,806,157)  $15,337,128   $(1,469,029)
Unrealized loss on foreign currency translation   (117,074)       (117,074)
Total comprehensive loss   (16,923,231)   15,337,128    (1,586,103)
Comprehensive loss attributable to non-controlling interest   (1,026,890)   1,026,890     
Comprehensive loss - Scorpius Holdings, Inc.  $(15,896,341)  $14,310,238   $(1,586,103)

 

 

 

 

 
 

  

SCORPIUS HOLDINGS, INC.

Unaudited Pro Forma Consolidated Statements of Operations and Comprehensive Loss

 

 

             
   Year Ended December 31, 2024 
   Previously   Pro Forma   Pro Forma 
   Reported   Adjustments(j)  Adjusted 
             
Revenue  $6,243,022   $(6,210,522)  $32,500 
                
Operating expenses:               
Cost of revenues   3,196,245    (3,196,245)    
Research and development   14,326,918    (13,509,084)   817,834 
Selling, general and administrative   21,570,874    (12,299,133)   9,271,741 
Loss on impairment of long-lived assets   1,939,246    (1,669,505)   269,741 
Change in fair value of contingent earn-out receivable, related party   (1,190,000)       (1,190,000)
Total operating expenses   39,843,283    (30,673,967)   9,169,316 
                
Operating loss   (33,600,261)   24,463,445    (9,136,816)
                
Interest income   22,230        22,230 
Interest expense   (953,173)   937,787    (15,386)
Unrealized gain on short-term investments   999        999 
Change in fair value of related party receivable   (330,000)       (330,000)
Change in fair value of convertible promissory notes, related party   280,950    (108,800)(m)   172,150 
Change in fair value of non-convertible promissory notes, related party   (19,000)       (19,000)
Change in fair value of warrant liability   469,800        469,800 
Loss on debt extinguishment   (560,000)       (560,000)
Other income   1,107,501        1,107,501 
Other expense   (746,834)   566,979    (179,855)
Total non-operating expense   (727,527)   1,395,966    668,439 
                
Net loss before income taxes   (34,327,788)   25,859,411    (8,468,377)
Income tax benefit            
Net loss   (34,327,788)   25,859,411    (8,468,377)
Net loss - non-controlling interest   (1,519,945)   1,519,945     
Net loss attributable to Scorpius Holdings, Inc.  $(32,807,843)  $24,339,466   $(8,468,377)
                
Weighted-average common shares outstanding, basic and diluted   2,515,742        2,515,742 
                
Net loss per common share attributable to Scorpius Holdings, Inc., basic and diluted  $(13.04)  $9.67   $(3.37)
                
Comprehensive loss               
Net loss  $(34,327,788)  $25,859,411   $(8,468,377)
Unrealized gain on foreign currency translation   175,233        175,233 
Total comprehensive loss   (34,152,555)   25,859,411    (8,293,144)
Comprehensive loss attributable to non-controlling interest   (1,519,945)   1,519,945     
Comprehensive loss - Scorpius Holdings, Inc.  $(32,632,610)  $24,339,466   $(8,293,144)

 

 

 
 

 

 

SCORPIUS HOLDINGS, INC.

Unaudited Pro Forma Consolidated Statements of Operations and Comprehensive Loss

 

             
   Year Ended December 31, 2023 
   Previously
Reported
   Pro Forma
Adjustments
(j)  Pro Forma
Adjusted
 
             
Revenue  $6,994,838   $(6,892,338)  $102,500 
                
Operating expenses:               
Cost of revenues   2,736,998    (2,736,998)    
Research and development   20,119,791    (15,391,763)   4,728,028 
Selling, general and administrative   26,170,221    (12,964,297)   13,205,924 
Total operating expenses   49,027,010    (31,093,058)   17,933,952 
                
Operating loss   (42,032,172)   24,200,720    (17,831,452)
                
Interest income   457,189        457,189 
Interest expense   (776,838)   758,011    (18,827)
Unrealized gain on short-term investments   123,044        123,044 
Other (expense) income   (104,822)   124,088    19,266 
Total non-operating expense   (301,427)   882,099    580,672 
                
Net loss from continuing operations before income taxes   (42,333,599)   25,082,819    (17,250,780)
Income tax benefit from continuing operations   571,120        571,120 
Net loss from continuing operations   (41,762,479)   25,082,819    (16,679,660)
Net loss from discontinued operations before income taxes   (5,005,518)       (5,005,518)
Income tax expense from discontinued operations   (65,189)       (65,189)
Net loss from discontinued operations   (5,070,707)       (5,070,707)
Net loss   (46,833,186)   25,082,819    (21,750,367)
Net loss - non-controlling interest   (1,616,018)   1,616,018     
Net loss attributable to Scorpius Holdings, Inc.  $(45,217,168)  $23,466,801   $(21,750,367)
                
Weighted-average common shares outstanding, basic and diluted   130,120        130,120 
                
Net loss per share, basic and diluted - continuing operations  $(308.53)  $180.34   $(128.19)
Net loss per share, basic and diluted - discontinued operations   (38.97)       (38.97)
Net loss per common share attributable to Scorpius Holdings, Inc., basic and diluted  $(347.50)  $180.35   $(167.16)
                
Comprehensive loss               
Net loss  $(46,833,186)  $25,082,819   $(21,750,367)
Unrealized loss on foreign currency translation   (3,047)       (3,047)
Total comprehensive loss   (46,836,233)   25,082,819    (21,753,414)
Comprehensive loss attributable to non-controlling interest   (1,616,018)   1,616,018     
Comprehensive loss - Scorpius Holdings, Inc.  $(45,220,215)  $23,466,801   $(21,753,414)

 

 

 

 

 
 

 

Notes to Unaudited Pro Forma Consolidated Financial Information

 

Note 1 – Pro Forma Adjustments

 

(a)Derecognition of prepaid expenses and other current assets with a carrying value of approximately $1.1 million as of September 30, 2025, including prepaid software of $0.1 million, prepaid manufacturing of $0.2 million, and contract assets of $0.8 million.
(b)Derecognition of raw material inventory with a carrying value of approximately $0.2 million as of September 30, 2025.
(c)Derecognition of property and equipment with a carrying value of approximately $8.4 million as of September 30, 2025, including lab equipment of $7.1 million and leasehold improvements of $1.0 million.
(d)Derecognition of operating lease right-of-use assets with a carrying value of approximately $0.6 million and operating lease liabilities of approximately $0.7 million as of September 30, 2025.
(e)Derecognition of finance lease right-of-use assets with a carrying value of approximately $9.6 million and finance lease liabilities of approximately $6.1 million as of September 30, 2025.
(f)Derecognition of lease-related deposits with a carrying value of approximately $0.1 million as of September 30, 2025.
(g)Previously reported amounts for convertible and non-convertible promissory notes payable, related party reflect the Company’s accounting under ASC 815, Derivatives and Hedging (“ASC 815”) and its elections to measure the instruments at fair value (the “fair value option”) under ASC 825, Financial Instruments (“ASC 825”). As a result, these instruments are required to be recorded at their initial fair value on the date of issuance and remeasured at each balance sheet date thereafter. Subsequent changes in their estimated fair value are recognized as a change in the fair value of the convertible and non-convertible promissory notes, related party, in the statements of operations and comprehensive loss. The Company does not separately report interest attributable to financial instruments accounted for pursuant to the fair value option because such interest is included in the determination of fair value of those financial instruments and changes thereto.

 

The Collateral Agent received proceeds of $15,219,552, net of fees and expenses of $1,033,595, that were applied against the Company’s debt as follows:

     
   Allocation of Proceeds 
2025 Non-Convertible Promissory Notes, Related Party     
Principal  $9,391,765 
Accrued Interest   186,620 
Redemption Premium   725,288 
    10,303,673 
December 2024 Secured Convertible Notes, Related Party     
Principal   2,971,115 
Interest and Make-Whole   1,371,020 
Late Fees   126,846 
Redemption Premium   446,898 
    4,915,879 
Total Proceeds  $15,219,552 

 

 

 

 
 

 

 

The aggregate amount, inclusive of principal, interest, make-whole, late fees, and redemption premiums, owed to the holders of the December 2024 Secured Convertible Notes, Related Party and 2025 Non-Convertible Promissory Notes, Related Party was $14.9 million immediately following the closing of the sale as follows:

     
   Remaining 
2025 Non-Convertible Promissory Notes, Related Party (measured at amortized cost)  $485,888 
December 2024 Secured Convertible Notes, Related Party (measured at amortized cost)   14,460,205 
Aggregate Remaining Debt Following Asset Sale  $14,946,093 
      

The components of the proceeds allocation and the aggregate remaining amount above have been presented on the accrual basis of accounting using amortized cost which is different than fair value measurement principles. The Company has determined it impractical to estimate fair value of the accompanying pro forma adjustments and pro forma adjusted amounts for inclusion in this filing. As a result, the pro forma adjusted amounts reflect the aggregate remaining amount above for the respective instruments.

 

The following components comprise pro forma convertible promissory notes payable, related party at September 30, 2025:

   Convertible
Promissory Notes
Payable, Related
Party
 
     
December 2024 Secured Convertible Notes, Related Party (measured at amortized cost)  $14,460,205 
Restated Elusys Convertible Note, Related Party (measured at fair value)   720,000 
Convertible promissory notes payable, related party  $15,180,205 
      
(h)Recognition of a preliminary loss on foreclosure of approximately $18.5 million as of September 30, 2025 based on the difference between the carrying value of the assets disposed of and the liabilities extinguished or adjusted as described herein.
(i)The Company’s CDMO and research and development activities were principally conducted by its subsidiaries Pelican Therapeutics, Inc., Skunkworx Bio, Inc., and Scorpius Biomanufacturing, Inc. The accompanying unaudited pro forma consolidated statements of operations and comprehensive loss reflect management’s estimates of the effects of the pro forma unaudited condensed consolidated balance sheet adjustments assuming those adjustments were made as of the beginning of the respective year presented. Management’s overarching assessment of the transaction is that the disposition of substantially all non-cash assets and workforce is analogous to a divestiture of those subsidiaries, that is, all results of operations of these subsidiaries have been removed as pro forma adjustments in the unaudited pro forma consolidated statements of operations and comprehensive loss.
(j)The $4,915,879 that was settled with proceeds from the foreclosure sale represented approximately 25% of the $19,376,084 balance of the December 2024 Secured Convertible Notes, Related Party measured at amortized cost immediately prior to the transaction. Loss on debt extinguishment of $2,647,000 for the nine months ended September 30, 2025 related solely to the December 2024 Secured Convertible Notes, Related Party. Management applied the 25% as its estimate, resulting in a pro forma adjustment of $661,750.
(k)The $10,303,673 that was settled with proceeds from the foreclosure sale represented the balance at amortized cost of twenty-four of the twenty-five individual instruments comprising the 2025 Non-Convertible Promissory Notes, Related Party outstanding at the transaction date. As each instrument is measured at fair value, the $1,200,000 pro forma adjustment to change in fair value of non-convertible promissory notes, related party is specifically attributable to the twenty-four instruments while that $100,000 pro forma adjusted balance is specifically attributable to the one instrument outstanding immediately following the transaction with a balance of $485,888 measured at amortized cost.
(l)The $4,915,879 that was settled with proceeds from the foreclosure sale represented approximately 25% of the $19,376,084 balance of the December 2024 Secured Convertible Notes, Related Party measured at amortized cost immediately prior to the transaction. Of the $7,791,321 reported as change in fair value of convertible promissory notes, related party for the nine months ended September 30, 2025, $6,521,321 related to the December 2024 Secured Convertible Notes, Related Party. Management applied the 25% as its estimate, resulting in a pro forma adjustment of $1,630,330.
(m)Change in fair value of convertible promissory notes, related party for the year ended December 31, 2024 attributable to the December 2024 Secured Convertible Notes, Related Party was $435,200. Changes in fair value related to other convertible promissory notes, related party contributed to the offsetting $154,250 that resulted in the $280,950 reported as change in fair value of convertible promissory notes, related party for the year ended December 31, 2024. Management applied the same 25% as its estimate, resulting in a pro forma adjustment of $108,800.

 

 

 
 

 

Note 2 – Income Taxes

 

The pro forma adjustments do not reflect income tax effects related to the foreclosure sale due to net loss carryforwards, valuation allowances, tax attributes, non-taxable nature of the transaction. Actual tax impacts may differ materially.

 

 

Note 3 – Management’s Limitations and Assumptions

 

The unaudited pro forma condensed consolidated financial information does not reflect:

·Any future costs or savings resulting from the foreclosure sale
·Any changes in the Company’s capital structure other than the partially reduced indebtedness from the foreclosure sale proceeds
·Any impairment charges or restructuring costs that may be recognized in the future periods.

 

 

FAQ

What major event does Scorpius Holdings (SCPX) describe in this 8-K/A?

Scorpius Holdings reports a December 10, 2025 foreclosure on substantially all non-cash CDMO and research assets. The collateral agent sold these assets and used the proceeds to partially repay secured notes, leading to discontinued operations presentation and updated pro forma financial statements.

How much debt repayment came from the Scorpius Holdings foreclosure sale?

The collateral agent received $15,219,552 in net proceeds from the foreclosure sale, after $1,033,595 of fees and expenses. These proceeds were allocated to principal, interest, make-whole, late fees, and redemption premiums on related-party non-convertible and secured convertible notes.

What debt remains for Scorpius Holdings after applying foreclosure proceeds?

After applying foreclosure proceeds, aggregate remaining related-party secured debt is $14,946,093. This includes $485,888 of 2025 non-convertible promissory notes and $14,460,205 of December 2024 secured convertible notes, both measured at amortized cost on an accrual basis.

How did the foreclosure affect Scorpius Holdings’ pro forma balance sheet?

Pro forma at September 30, 2025, total assets drop to $867,647, mainly cash and current items, after removing foreclosed property, equipment, leases, and deposits. Total liabilities are $25,299,258, resulting in a total stockholders’ deficit of $24,431,611 including non-controlling interests.

What is the pro forma profitability of Scorpius Holdings after the asset foreclosure?

For the nine months ended September 30, 2025, pro forma revenue is reduced to zero and pro forma net loss attributable to Scorpius Holdings is $1,469,029. This compares to a previously reported net loss attributable to Scorpius of $15,779,267 before adjusting for the disposition.

How were employees impacted by the Scorpius Holdings foreclosure transaction?

Employment of all CDMO employees ended on December 10, 2025, the foreclosure closing date. A majority of those former employees joined Velocity Bioworks, Inc., a wholly owned subsidiary of Tivic Health Systems, Inc., which acquired the foreclosed CDMO assets in the transaction.

Why does Scorpius Holdings treat the foreclosed business as discontinued operations?

The transaction meets criteria for discontinued operations presentation because it involves a significant disposal of assets and related operations. The company’s pro forma financial statements reclassify the foreclosed CDMO and research activities as discontinued, isolating ongoing results from the remaining business segments.

Filing Exhibits & Attachments

4 documents
Scorpius Holdings

OTC:SCPX

View SCPX Stock Overview

SCPX Rankings

SCPX Latest News

SCPX Latest SEC Filings

SCPX Stock Data

1.53M
61.11M
Biotechnology
Pharmaceutical Preparations
Link
United States
MORRISVILLE